ZGN heads into the summer with an unusual alignment: a fresh analyst upgrade, a put/call ratio near its most bullish extreme of the past year, and insider sells that look like routine award liquidations rather than a vote of no confidence.
The standout this week is TD Cowen's Oliver Chen, who upgraded ZGN to Buy from Hold on May 20 and lifted his price target to $15 from $13. That upgrade follows a prior target raise on May 1, when Chen kept his Hold but moved to $13 from $11. Two target increases inside three weeks from the same analyst signals rising conviction. At $15, Chen's target stands roughly 20% above the $12.52 close — notable given that the consensus mean target of $11.50 sits below the current price, suggesting a wide dispersion of views on the Street. With seven buys and three holds, the overall lean is constructive, but valuation comfort clearly varies. Some caution is warranted: the B of A Securities downgrade from January 2026 (to Neutral, target $11.20) still reflects the more skeptical end of the panel, and Morgan Stanley's Underweight initiation from late 2024 at $7.20 represents a very different view of where the stock belongs.
The options market is sending a notably bullish signal. The put/call ratio has collapsed to 0.16, more than 1.4 standard deviations below its 20-day average of 0.45. That is close to the lowest defensive positioning seen in ZGN options over the past year — the 52-week low on the PCR is 0.00, but 0.16 is well into unusual territory. The shift is sharp: as recently as mid-April the PCR ran above 1.0, reflecting meaningful hedging demand. That hedging has been unwound almost entirely, replaced by call-heavy positioning that aligns with the upgrade cycle.
Short interest tells a quieter story. At just 1.4% of the free float, short positioning is low and not moving in a way that creates urgency. It eased about 1.5% over the past week, after drifting higher through most of April and early May. Cost to borrow is minimal at 0.62% — down roughly 30% from a month ago — and borrow availability is comfortable at 218%, meaning there are roughly two shares available to lend for every one already borrowed. The lending market is not tight by any measure.
The insider picture is worth contextualising rather than alarming. On May 8, the acting CEO, CFO, and several division heads all sold shares at $13.12. The timing follows share awards granted the day before on May 7. These look like standard award-and-sell sequences tied to equity compensation plans, rather than discretionary negative signals. The CFO sold $75,676 worth; the acting CEO sold $250,658 worth. Neither figure is material relative to the company's scale, and the 90-day net insider value across all transactions is a positive $708,072 — largely reflecting the award grants themselves. The founding family's vehicle, Monterubello, holds 57% of shares and remains unchanged. Temasek sits at 10%, also flat.
Valuation multiples have drifted lower over the past 30 days: the PE has slipped from roughly 24x to 23.6x, and EV/EBITDA has edged down to 7.7x. Neither represents a dramatic re-rating, but the direction is mildly easing, which gives the upgrade some room. Among comparable names this week, LEVI and PVH both fell 3-4%, and RL dropped nearly 5%. ZGN gained 1% on the week — a clear outperformance within the peer group, consistent with a stock responding to positive sentiment rather than a broader sector bid.
The next earnings event is scheduled for September 3. Between now and then, the question is whether the call-heavy options positioning and TD Cowen's fresh Buy translate into broader analyst convergence — or whether the Street's majority caution reasserts itself.
See the live data behind this article on ORTEX.
Open ZGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
